한타바이러스 시장 규모, 점유율 및 동향 분석 보고서 : 유형별, 지역별 및 부문별 예측(2026-2033년)

Hantavirus Market Summary

The global hantavirus market size was valued at USD 64.8 million in 2025 and is projected to grow from USD 68.3 million in 2026 to USD 102.0 million by 2033, at a CAGR of 5.9% from 2026 to 2033. The North America Hantavirus market held the largest global share of 36.1% in 2025. The global market is growing, driven by the increasing incidence of infections across endemic and non-endemic regions worldwide.

Healthcare providers are expanding the adoption of molecular diagnostic technologies to improve early detection, clinical accuracy, and patient management efficiency. Rising awareness of zoonotic viral diseases is strengthening the use of RT-PCR and serological testing across hospitals, diagnostic laboratories, and public health institutions. Severe manifestations of Hantavirus Pulmonary Syndrome (HPS) are increasing demand for respiratory support systems, intensive care management, and specialized hospital services. Continuous improvements in infectious disease testing infrastructure, laboratory automation, and molecular biology technologies are further supporting market expansion, while rapid diagnostic integration in emergency care enhances outbreak response and clinical decision-making. For instance, in May 2026, the CDC issued Health Alert Network notice CDCHAN-00529 reporting an Andes virus cruise ship outbreak confirmed on May 2, 2026 and strain confirmation on May 6, 2026, with WHO reporting 10 cases, including 8 confirmed and 3 deaths as of May 18, 2026.

The growing burden of Hemorrhagic Fever with Renal Syndrome (HFRS) in Asia Pacific is contributing significantly to the commercial growth of the Hantavirus market. Diagnostic laboratories are increasingly incorporating high-sensitivity molecular assays to strengthen outbreak surveillance, epidemiological monitoring, and confirmatory disease testing activities. Hospitals and critical care centers are focusing on advanced renal support systems and emergency treatment solutions for severe hantavirus-associated complications. Expanding research efforts related to antiviral therapies, monoclonal antibodies, and immunotherapy-based treatment approaches are improving the overall therapeutic landscape of the market. Rapid advancements in molecular testing platforms are enhancing operational efficiency and reducing diagnostic turnaround times across healthcare facilities. Increasing collaborations between diagnostic manufacturers and healthcare organizations are further supporting product development activities and strengthening commercial penetration in high-risk regions globally.

Global Hantavirus Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global Hantavirus market report based on type and region:

• Type Outlook (Revenue, USD Million, 2021 - 2033)
• Therapeutic
  • Product Type
  • Vaccine
  • Antiviral Therapies
  • Immunotherapies & Biologics
  • Supportive Care Therapies
  • Route of Administration
  • Intravenous (IV)
  • Intramuscular (IM)
  • Other
  • Procurement Channel
  • Public
  • Institutional
• Diagnostic
  • Test Type
  • Molecular Diagnostic Tests
  • RT-PCR Molecular Diagnostic Tests
  • Real-Time RT-PCR Assays
  • Serological Diagnostic Tests
  • ELISA Tests
  • Rapid Antibody Tests
  • Others
  • Others
  • End Use
  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Government & Public Health Agencies
  • Research Institutes
  • Disease Type
  • Hantavirus Pulmonary Syndrome (HPS)
  • Hemorrhagic Fever with Renal Syndrome (HFRS)
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Hantavirus Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis
  • 3.3.4. Patent Expiry Analysis
  • 3.3.5. Pricing Analysis

Chapter 4. Hantavirus Market: Type Business Analysis

• 4.1. Type Market Share, 2025 & 2033
• 4.2. Type Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (USD Million)
• 4.4. Therapeutic
  • 4.4.1. Therapeutic Market, 2021 - 2033 (USD Million)
  • 4.4.2. Product Type
    • 4.4.2.1. Product Type Market, 2021 - 2033 (USD Million)
    • 4.4.2.2. Vaccine
      • 4.4.2.2.1. Vaccine Market, 2021 - 2033 (USD Million)
    • 4.4.2.3. Antiviral Therapies
      • 4.4.2.3.1. Antiviral Therapies Market, 2021 - 2033 (USD Million)
    • 4.4.2.4. Immunotherapies & Biologics
      • 4.4.2.4.1. Immunotherapies & Biologics Market, 2021 - 2033 (USD Million)
    • 4.4.2.5. Supportive Care Therapies
      • 4.4.2.5.1. Supportive Care Therapies Market, 2021 - 2033 (USD Million)
  • 4.4.3. Route of Administration
    • 4.4.3.1. Route of Administration Market, 2021 - 2033 (USD Million)
    • 4.4.3.2. Intravenous (IV)
      • 4.4.3.2.1. Intravenous (IV) Market, 2021 - 2033 (USD Million)
    • 4.4.3.3. Intramuscular (IM)
      • 4.4.3.3.1. Intramuscular (IM) Market, 2021 - 2033 (USD Million)
    • 4.4.3.4. Other
      • 4.4.3.4.1. Other Market, 2021 - 2033 (USD Million)
  • 4.4.4. Procurement Channel
    • 4.4.4.1. Procurement Channel Market, 2021 - 2033 (USD Million)
    • 4.4.4.2. Public
      • 4.4.4.2.1. Public Market, 2021 - 2033 (USD Million)
    • 4.4.4.3. Institutional
      • 4.4.4.3.1. Institutional Market, 2021 - 2033 (USD Million)
• 4.5. Diagnostic
  • 4.5.1. Diagnostic Market, 2021 - 2033 (USD Million)
  • 4.5.2. Test Type
    • 4.5.2.1. Test Type Market, 2021 - 2033 (USD Million)
    • 4.5.2.2. Molecular Diagnostic Tests
      • 4.5.2.2.1. Molecular Diagnostic Tests Market, 2021 - 2033 (USD Million)
      • 4.5.2.2.2. RT-PCR Molecular Diagnostic Tests
        • 4.5.2.2.2.1. RT-PCR Molecular Diagnostic Tests Market, 2021 - 2033 (USD Million)
      • 4.5.2.2.3. Real-Time RT-PCR Assays
        • 4.5.2.2.3.1. Real-Time RT-PCR Assays Market, 2021 - 2033 (USD Million)
    • 4.5.2.3. Serological Diagnostic Tests
      • 4.5.2.3.1. Serological Diagnostic Tests Market, 2021 - 2033 (USD Million)
      • 4.5.2.3.2. ELISA Tests
        • 4.5.2.3.2.1. ELISA Tests Market, 2021 - 2033 (USD Million)
      • 4.5.2.3.3. Rapid Antibody Tests
        • 4.5.2.3.3.1. Rapid Antibody Tests Market, 2021 - 2033 (USD Million)
      • 4.5.2.3.4. Others
        • 4.5.2.3.4.1. Others Market, 2021 - 2033 (USD Million)
    • 4.5.2.4. Others
      • 4.5.2.4.1. Others Market, 2021 - 2033 (USD Million)
  • 4.5.3. End Use
    • 4.5.3.1. End Use Market, 2021 - 2033 (USD Million)
    • 4.5.3.2. Hospitals & Clinics
      • 4.5.3.2.1. Hospitals & Clinics Market, 2021 - 2033 (USD Million)
    • 4.5.3.3. Diagnostic Laboratories
      • 4.5.3.3.1. Diagnostic Laboratories Market, 2021 - 2033 (USD Million)
    • 4.5.3.4. Government & Public Health Agencies
      • 4.5.3.4.1. Government & Public Health Agencies Market, 2021 - 2033 (USD Million)
    • 4.5.3.5. Research Institutes
      • 4.5.3.5.1. Research Institutes Market, 2021 - 2033 (USD Million)
  • 4.5.4. Disease Type
    • 4.5.4.1. Disease Type Market, 2021 - 2033 (USD Million)
    • 4.5.4.2. Hantavirus Pulmonary Syndrome (HPS)
      • 4.5.4.2.1. Hantavirus Pulmonary Syndrome (HPS) Market, 2021 - 2033 (USD Million)
    • 4.5.4.3. Hemorrhagic Fever with Renal Syndrome (HFRS)
      • 4.5.4.3.1. Hemorrhagic Fever with Renal Syndrome (HFRS) Market, 2021 - 2033 (USD Million)

Chapter 5. Hantavirus Market: Regional Estimates & Trend Analysis

• 5.1. Regional Market Share Analysis, 2025 & 2033
• 5.2. Regional Market Dashboard
• 5.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
• 5.4. North America
  • 5.4.1. North America Hantavirus Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
  • 5.4.2. U.S.
    • 5.4.2.1. Key Country Dynamics
    • 5.4.2.2. Target Disease Prevalence
    • 5.4.2.3. Regulatory Framework
    • 5.4.2.4. Reimbursement Framework
    • 5.4.2.5. U.S. Hantavirus Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4.3. Canada
    • 5.4.3.1. Key Country Dynamics
    • 5.4.3.2. Target Disease Prevalence
    • 5.4.3.3. Regulatory Framework
    • 5.4.3.4. Reimbursement Framework
    • 5.4.3.5. Canada Hantavirus Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4.4. Mexico
    • 5.4.4.1. Key Country Dynamics
    • 5.4.4.2. Target Disease Prevalence
    • 5.4.4.3. Regulatory Framework
    • 5.4.4.4. Reimbursement Framework
    • 5.4.4.5. Mexico Hantavirus Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Europe
  • 5.5.1. Europe Hantavirus Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.2. UK
    • 5.5.2.1. Key Country Dynamics
    • 5.5.2.2. Target Disease Prevalence
    • 5.5.2.3. Regulatory Framework
    • 5.5.2.4. Reimbursement Framework
    • 5.5.2.5. UK Hantavirus Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.3. Germany
    • 5.5.3.1. Key Country Dynamics
    • 5.5.3.2. Target Disease Prevalence
    • 5.5.3.3. Regulatory Framework
    • 5.5.3.4. Reimbursement Framework
    • 5.5.3.5. Germany Hantavirus Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.4. France
    • 5.5.4.1. Key Country Dynamics
    • 5.5.4.2. Target Disease Prevalence
    • 5.5.4.3. Regulatory Framework
    • 5.5.4.4. Reimbursement Framework
    • 5.5.4.5. France Hantavirus Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.5. Italy
    • 5.5.5.1. Key Country Dynamics
    • 5.5.5.2. Target Disease Prevalence
    • 5.5.5.3. Regulatory Framework
    • 5.5.5.4. Reimbursement Framework
    • 5.5.5.5. Italy Hantavirus Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.6. Spain
    • 5.5.6.1. Key Country Dynamics
    • 5.5.6.2. Target Disease Prevalence
    • 5.5.6.3. Regulatory Framework
    • 5.5.6.4. Reimbursement Framework
    • 5.5.6.5. Spain Hantavirus Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.7. Denmark
    • 5.5.7.1. Key Country Dynamics
    • 5.5.7.2. Target Disease Prevalence
    • 5.5.7.3. Regulatory Framework
    • 5.5.7.4. Reimbursement Framework
    • 5.5.7.5. Denmark Hantavirus Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.8. Sweden
    • 5.5.8.1. Key Country Dynamics
    • 5.5.8.2. Target Disease Prevalence
    • 5.5.8.3. Regulatory Framework
    • 5.5.8.4. Reimbursement Framework
    • 5.5.8.5. Sweden Hantavirus Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.9. Norway
    • 5.5.9.1. Key Country Dynamics
    • 5.5.9.2. Target Disease Prevalence
    • 5.5.9.3. Regulatory Framework
    • 5.5.9.4. Reimbursement Framework
    • 5.5.9.5. Norway Hantavirus Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Asia Pacific
  • 5.6.1. Asia Pacific Hantavirus Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6.2. Japan
    • 5.6.2.1. Key Country Dynamics
    • 5.6.2.2. Target Disease Prevalence
    • 5.6.2.3. Regulatory Framework
    • 5.6.2.4. Reimbursement Framework
    • 5.6.2.5. Japan Hantavirus Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6.3. China
    • 5.6.3.1. Key Country Dynamics
    • 5.6.3.2. Target Disease Prevalence
    • 5.6.3.3. Regulatory Framework
    • 5.6.3.4. Reimbursement Framework
    • 5.6.3.5. China Hantavirus Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6.4. India
    • 5.6.4.1. Key Country Dynamics
    • 5.6.4.2. Target Disease Prevalence
    • 5.6.4.3. Regulatory Framework
    • 5.6.4.4. Reimbursement Framework
    • 5.6.4.5. India Hantavirus Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6.5. Australia
    • 5.6.5.1. Key Country Dynamics
    • 5.6.5.2. Target Disease Prevalence
    • 5.6.5.3. Regulatory Framework
    • 5.6.5.4. Reimbursement Framework
    • 5.6.5.5. Australia Hantavirus Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6.6. South Korea
    • 5.6.6.1. Key Country Dynamics
    • 5.6.6.2. Target Disease Prevalence
    • 5.6.6.3. Regulatory Framework
    • 5.6.6.4. Reimbursement Framework
    • 5.6.6.5. South Korea Hantavirus Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6.7. Thailand
    • 5.6.7.1. Key Country Dynamics
    • 5.6.7.2. Target Disease Prevalence
    • 5.6.7.3. Regulatory Framework
    • 5.6.7.4. Reimbursement Framework
    • 5.6.7.5. Thailand Hantavirus Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.7. Latin America
  • 5.7.1. Latin America Hantavirus Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.7.2. Brazil
    • 5.7.2.1. Key Country Dynamics
    • 5.7.2.2. Target Disease Prevalence
    • 5.7.2.3. Regulatory Framework
    • 5.7.2.4. Reimbursement Framework
    • 5.7.2.5. Brazil Hantavirus Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.7.3. Argentina
    • 5.7.3.1. Key Country Dynamics
    • 5.7.3.2. Target Disease Prevalence
    • 5.7.3.3. Regulatory Framework
    • 5.7.3.4. Reimbursement Framework
    • 5.7.3.5. Argentina Hantavirus Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.8. Middle East and Africa
  • 5.8.1. Middle East and Africa Hantavirus Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.8.2. South Africa
    • 5.8.2.1. Key Country Dynamics
    • 5.8.2.2. Target Disease Prevalence
    • 5.8.2.3. Regulatory Framework
    • 5.8.2.4. Reimbursement Framework
    • 5.8.2.5. South Africa Hantavirus Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.8.3. Saudi Arabia
    • 5.8.3.1. Key Country Dynamics
    • 5.8.3.2. Target Disease Prevalence
    • 5.8.3.3. Regulatory Framework
    • 5.8.3.4. Reimbursement Framework
    • 5.8.3.5. Saudi Arabia Hantavirus Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.8.4. UAE
    • 5.8.4.1. Key Country Dynamics
    • 5.8.4.2. Target Disease Prevalence
    • 5.8.4.3. Regulatory Framework
    • 5.8.4.4. Reimbursement Framework
    • 5.8.4.5. UAE Hantavirus Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.8.5. Kuwait
    • 5.8.5.1. Key Country Dynamics
    • 5.8.5.2. Target Disease Prevalence
    • 5.8.5.3. Regulatory Framework
    • 5.8.5.4. Reimbursement Framework
    • 5.8.5.5. Kuwait Hantavirus Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Competitive Landscape

• 6.1. Participant Overview
• 6.2. Company Market Position Analysis
• 6.3. Company Categorization
• 6.4. Strategy Mapping
• 6.5. Company Profiles/Listing
  • 6.5.1. F. Hoffmann-La Roche Ltd.
    • 6.5.1.1. Overview
    • 6.5.1.2. Financial Performance
    • 6.5.1.3. Product Benchmarking
    • 6.5.1.4. Strategic Initiatives
  • 6.5.2. Thermo Fisher Scientific Inc.
    • 6.5.2.1. Overview
    • 6.5.2.2. Financial Performance
    • 6.5.2.3. Product Benchmarking
    • 6.5.2.4. Strategic Initiatives
  • 6.5.3. QIAGEN N.V.
    • 6.5.3.1. Overview
    • 6.5.3.2. Financial Performance
    • 6.5.3.3. Product Benchmarking
    • 6.5.3.4. Strategic Initiatives
  • 6.5.4. Abbott Laboratories
    • 6.5.4.1. Overview
    • 6.5.4.2. Financial Performance
    • 6.5.4.3. Product Benchmarking
    • 6.5.4.4. Strategic Initiatives
  • 6.5.5. Bio-Rad Laboratories, Inc.
    • 6.5.5.1. Overview
    • 6.5.5.2. Financial Performance
    • 6.5.5.3. Product Benchmarking
    • 6.5.5.4. Strategic Initiatives
  • 6.5.6. Siemens Healthineers AG
    • 6.5.6.1. Overview
    • 6.5.6.2. Financial Performance
    • 6.5.6.3. Product Benchmarking
    • 6.5.6.4. Strategic Initiatives
  • 6.5.7. Danaher Corporation (Cepheid)
    • 6.5.7.1. Overview
    • 6.5.7.2. Financial Performance
    • 6.5.7.3. Product Benchmarking
    • 6.5.7.4. Strategic Initiatives
  • 6.5.8. Hologic, Inc.
    • 6.5.8.1. Overview
    • 6.5.8.2. Financial Performance
    • 6.5.8.3. Product Benchmarking
    • 6.5.8.4. Strategic Initiatives
  • 6.5.9. GC Biopharma Corp.
    • 6.5.9.1. Overview
    • 6.5.9.2. Financial Performance
    • 6.5.9.3. Product Benchmarking
    • 6.5.9.4. Strategic Initiatives
  • 6.5.10. Creative Diagnostics
    • 6.5.10.1. Overview
    • 6.5.10.2. Financial Performance
    • 6.5.10.3. Product Benchmarking
    • 6.5.10.4. Strategic Initiatives